flaviviru
genu
famili
flavivirida
contain
larg
number
viral
agent
capabl
caus
enceph
jaundic
flavivirus
arbovirus
transmit
human
popul
bite
infect
mosquito
tick
flavivirus
typic
contain
posit
sens
singlestrand
rna
genom
approxim
length
genom
encod
structur
protein
capsid
prm
envelop
nonstructur
protein
virus
envelop
diamet
around
appear
icosahedr
spheric
observ
electron
microscop
individu
member
dengu
denv
yellowfev
viru
yfv
japanes
enceph
viru
jev
tickborn
enceph
viru
tbev
west
nile
viru
wnv
caus
signific
morbid
mortal
worldwid
denv
major
public
health
concern
global
scale
estim
million
infect
million
clinic
case
patient
carri
diseas
asymptomat
howev
around
infect
individu
progress
sever
dengu
ill
character
plasma
leakag
lead
hypovolem
shock
hemorrhag
potenti
death
casefat
rate
individu
sever
dengu
high
untreat
appropri
clinic
manag
alphavirus
divers
group
virus
classifi
belong
group
iv
togavirida
famili
virus
thirti
member
alphaviru
group
abl
infect
wide
rang
vertebr
includ
human
rodent
fish
bird
hors
genom
level
alphavirus
consist
posit
sens
singlestrand
rna
genom
length
cap
polya
tail
alphaviru
particl
envelop
size
around
nm
diamet
electron
microscop
appear
spheric
nm
isometr
nucleocapsid
like
flavivirus
main
mode
transmiss
human
popul
via
bite
infect
mosquito
notabl
virus
infect
human
popul
includ
chikungunya
chikv
barmah
forest
viru
bfv
mayaro
viru
mayv
onyongnyong
viru
onnv
ross
river
viru
rrv
una
viru
tonat
viru
epidem
flaviviru
alphaviru
occur
global
annual
basi
differ
degre
sever
tabl
show
small
select
recent
flavivirusalphaviru
outbreak
worldwid
global
distribut
sever
flaviviru
alphaviru
infect
requir
accur
surveil
tool
time
diagnosi
ensur
infect
patient
obtain
best
medic
treatment
option
alert
author
possibl
outbreak
diseas
accur
method
diagnos
viral
agent
real
time
polymeras
chain
reaction
rtpcr
primer
probe
sequenc
complementari
viral
rna
design
cycl
seri
step
posit
sampl
seen
amplif
curv
rtpcr
instrument
process
complet
less
hour
significantli
assist
patient
manag
howev
member
flaviviru
alphaviru
famili
quit
heterogen
rna
level
therefor
difficult
design
singl
set
primer
probe
sequenc
detect
famili
genu
speci
level
exampl
denv
contain
four
serotyp
quit
divers
genom
level
like
current
dengu
rtpcr
assay
cdc
rtpcr
assay
detect
serotyp
use
individu
primer
pair
probe
type
assay
univers
detect
denv
serotyp
describ
assay
still
employ
primer
detect
subtyp
order
simplifi
improv
detect
alphavirus
flavivirus
clinic
sampl
develop
commerci
avail
assay
abl
detect
presenc
target
alphaviru
flaviviru
use
singl
primer
probe
set
type
assay
use
chemic
modif
reduc
complex
genom
base
enabl
screen
primer
probe
fewer
mismatch
develop
bia
amplif
effici
across
speci
greatli
reduc
fig
protocol
fig
deamin
cytosin
residu
nucleic
acid
uracil
intermedi
process
make
close
relat
speci
similar
genom
level
novel
method
ultim
mean
primer
probe
set
design
fewer
mismatch
abl
hybridis
previous
heterogen
target
region
higher
effici
thu
improv
pcr
amplif
speci
contain
larg
number
individu
pathogen
modif
process
genom
nucleic
acid
form
sacrific
specif
individu
type
primer
construct
detect
exact
organ
respons
diseas
method
use
success
detect
presenc
high
risk
hpv
clinic
sampl
presenc
pathogen
includ
noroviru
patient
gastrointestin
diseas
utilis
method
produc
panspeci
assay
detect
flaviviru
alphaviru
dengu
serotyp
success
appli
assay
screen
sampl
vanuatu
dengu
outbreak
interim
ethic
committe
compris
follow
member
ministri
health
mr
georg
taleo
director
gener
health
mr
len
tarivonda
director
public
health
mr
russel
tamata
director
hospit
cur
health
dr
posikai
samuel
tapo
director
cooper
servic
plan
polici
approv
studi
adult
provid
verbal
consent
either
children
includ
studi
synthet
dna
follow
virus
synthesis
sigma
castl
hill
australia
determin
specif
sensit
individu
pcr
compon
assay
flavivirus
wnv
zikv
yfv
tbev
mvev
aphavirus
chikv
bfv
rrv
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
venezuelan
equin
enceph
viru
veev
middleburg
viru
mv
ndumu
viru
nv
dna
consist
singl
strand
dna
sequenc
contain
ident
primer
probe
bind
site
present
viral
nucleic
acid
target
viru
addit
size
amplicon
amplifi
viral
nucleic
acid
ensur
result
gener
consist
would
occur
nativ
viru
tabl
list
nucleic
acid
whole
organ
use
determin
sensit
specif
pan
flaviviru
alphaviru
dengu
assay
addit
qualiti
assur
panel
denv
chikv
zikv
obtain
qcmd
qualiti
control
molecular
diagnost
glasgow
scotland
panel
contain
inactiv
whole
viral
particl
rang
differ
media
serial
dilut
control
convert
form
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
nucleic
acid
viral
particl
reconstitut
accord
manufactur
instruct
lower
limit
detect
llod
studi
vircel
total
run
control
whole
viral
particl
provid
certif
specifi
copi
number
vircel
chikungunya
rna
sampl
provid
certif
specifi
copi
number
individu
two
fold
serial
dilut
total
volum
molecular
grade
water
gbioscienc
st
loui
usa
human
serum
mimic
actual
clinic
sampl
sigma
sydney
australia
sampl
convert
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
nucleic
acid
purif
complet
use
gsmini
autom
nucleic
extract
platform
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
sampl
purif
ten
pcr
replic
dilut
perform
llod
determin
lowest
dilut
ten
pcr
replic
posit
assay
quantifi
copi
number
provid
manufactur
vircel
reli
upon
determin
copi
per
pcr
contriv
urin
sampl
gener
spike
whole
viral
particl
freshli
collect
neg
urin
water
five
extract
process
control
epc
ad
sampl
prior
convers
epc
consist
intact
phage
ad
sampl
control
proper
sampl
convers
revers
transcript
monitor
pcr
inhibit
sampl
convert
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
nucleic
acid
purif
complet
use
gsmini
autom
nucleic
extract
platform
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
order
maximis
concentr
potenti
crossreact
virus
tabl
sampl
eluat
amplirun
control
extract
along
epc
posit
control
vircel
amplirun
denvzikvchikv
total
run
control
includ
run
confirm
compon
assay
work
optim
nucleic
acid
amplirun
control
provid
concentr
copi
per
give
total
concentr
eluat
copi
viral
nucleic
acid
nucleic
acid
convers
extract
carri
valid
panel
handl
detail
manufactur
materi
along
epc
convert
form
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
bisulphit
convers
sampl
extract
gsmini
autom
nucleic
extract
platform
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
serum
plasma
sampl
patient
suspect
denv
infect
collect
port
vila
central
hospit
efat
vanuatu
decemb
march
materi
along
epc
process
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
bisulphit
convers
sampl
extract
gsmini
autom
nucleic
extract
platform
use
easyscreen
sampl
process
kit
genet
signatur
sydney
australia
accord
manufactur
instruct
follow
primer
probe
set
avail
genet
signatur
panflaviviru
panalphaviru
pandengu
zika
viru
west
nile
viru
yellow
fever
viru
tickborn
enceph
viru
st
loui
enceph
viru
murray
valley
enceph
viru
chikungunya
ross
river
viru
barmah
forest
viru
eastern
equin
enceph
viru
western
equin
enceph
viru
venezuelan
equin
enceph
viru
follow
sampl
extract
elut
convert
nucleic
acid
materi
ad
combin
pcr
mastermix
compon
use
easyscreen
flaviviru
dengu
alphaviru
detect
kit
genet
signatur
sydney
australia
thermocycl
consist
cycl
revers
transcript
minut
follow
taq
polymeras
activ
minut
cycl
amplif
second
second
data
collect
second
second
pcr
amplif
carri
use
either
biorad
biorad
hercul
usa
mic
biomolecular
system
sydney
australia
platform
diseas
incid
given
island
compar
averag
incid
whole
countri
use
zscore
test
two
popul
proport
avail
http
p
valu
consid
statist
signific
prior
test
sampl
small
studi
perform
determin
altern
sampl
type
mouth
swab
urin
sampl
patient
suspect
denv
infect
could
use
less
invas
altern
sampl
type
four
match
urin
plasma
mouth
swab
sampl
taken
extract
use
standard
procedur
describ
although
denv
rna
could
detect
three
sampl
type
signific
ct
lag
observ
urin
mouth
swab
compar
plasma
fig
data
indic
approxim
fold
viru
serumplasma
sampl
compar
matrix
demonstr
serumplasma
prefer
test
sampl
type
data
also
agre
previou
studi
use
viral
rna
antigen
assay
total
sampl
test
tabl
vanuatu
outbreak
origin
test
algorithm
consist
screen
sampl
panflaviviru
panalphaviru
pandengu
first
day
test
panflaviviruspandengu
posit
sampl
subsequ
type
dengu
type
primer
show
serotyp
respons
current
outbreak
order
provid
rapid
diagnost
primer
includ
request
hospit
initi
screen
assay
negat
need
perform
subsequ
reflex
test
sampl
still
abil
detect
new
virus
emerg
molecular
test
avail
port
vila
central
hospit
detect
dengu
viru
thu
sampl
previous
test
antigenigg
igm
obtain
patient
month
decemb
februari
march
patient
attend
hospit
suspect
dengu
infect
screen
assay
fig
show
posit
week
decemb
march
molecular
test
carri
march
fig
show
number
dengu
infect
age
age
gener
popul
seen
figur
number
dengu
posit
sampl
mirror
age
popul
result
gener
shown
assay
abl
sensit
specif
detect
presenc
flaviviru
alphaviru
dengu
use
synthet
construct
whole
viral
rna
whole
viral
particl
contriv
clinic
sampl
well
valid
panel
initi
assay
valid
method
use
test
clinic
sampl
obtain
dengu
outbreak
vanuatu
tradit
detect
flavivirus
alphavirus
clinic
sampl
larg
reli
enzym
immuno
assay
well
establish
eia
assay
zikv
viru
show
high
degre
cross
reactiv
dengu
posit
sampl
addit
shown
dengu
igg
igm
assay
cross
react
zikvposit
patient
sampl
furthermor
convent
enzym
immuno
assay
unabl
differenti
individu
denv
serotyp
gener
less
sensit
molecular
assay
method
detect
unknown
aetiolog
agent
diseas
includ
use
microarray
fabric
larg
number
oligonucleotid
probe
specif
individu
pathogen
hybridis
clinic
sampl
array
use
detect
presenc
viral
genom
infect
individu
addit
advent
next
gener
sequenc
continu
reduct
cost
associ
technolog
feasibl
appli
method
viral
discoveri
howev
new
method
still
costli
time
consum
lack
sensit
compar
establish
method
rtpcr
gener
posit
signal
around
hour
main
advantag
molecular
test
includ
lack
cross
reactiv
close
relat
speci
improv
sensit
pathogen
detect
rtpcr
assay
design
specif
target
individu
serotyp
howev
assay
abl
target
member
complex
group
flaviviru
alphaviru
use
singl
primer
probe
set
without
produc
pcr
bia
due
mismatch
primer
probe
site
case
convent
pcr
assay
requir
use
multipl
primer
probe
set
detect
viru
individu
addit
flaviviru
alphavirus
show
differ
global
distribut
virus
yfv
endem
africa
tbev
endem
eurasia
jev
southeast
asia
mvev
australia
papua
new
guinea
slev
mainli
found
unit
state
rare
canada
mexico
similar
geograph
pattern
also
seen
alphavirus
one
advantag
current
panflaviviruspanalphaviruspandengu
screen
test
assay
use
global
region
quickli
detect
presenc
unknown
viral
infect
viral
famili
identifi
individu
type
reaction
use
determin
pathogen
respons
diseas
simplifi
reduc
cost
broad
screen
approach
diseas
outbreak
pathogen
surveil
human
vector
panspeci
assay
shown
amplifi
member
group
use
singl
primer
probe
set
use
synthet
construct
panalphaviru
assay
abl
detect
chikv
weev
eeev
veev
rrv
nv
bfv
nv
linear
rang
least
copi
per
reaction
chikv
eeev
veev
rrv
nv
bfv
nv
copi
per
reaction
virus
fig
panflaviviru
assay
abl
detect
zikv
yfv
wnv
tbev
copi
per
reaction
lowest
dilut
test
use
construct
fig
contriv
clinic
sampl
prepar
spike
either
serum
urin
whole
viru
particl
process
determin
sampl
type
detriment
assay
perform
compar
process
viral
particl
molecular
grade
water
signific
differ
observ
determin
ct
valu
epc
panflaviviru
panalphaviru
pandengu
assay
indic
assay
compat
routin
clinic
sampl
type
use
flaviviru
alphaviru
molecular
test
llod
studi
conduct
use
whole
intact
viral
particl
inactiv
order
render
noninfecti
result
shown
demonstr
zikv
chikv
inactiv
whole
viru
particl
pool
serum
matrix
sensit
assay
around
copi
per
reaction
panflaviviru
panalphaviru
pandengu
assay
use
rna
spike
serum
sensit
less
possibl
due
degrad
rna
matrix
cross
reactiv
observ
compon
assay
use
wide
rang
viral
materi
includ
adenoviru
bk
viru
coronaviru
cmv
enteroviru
enteroviru
epsteinbarr
viru
herp
simplex
viru
herp
simplex
viru
influenza
influenza
influenza
b
respiratori
syncyti
viru
subtyp
respiratori
syncyti
viru
subtyp
b
rhinoviru
varicella
zoster
viru
posit
extract
control
gave
desir
signal
thu
confirm
neg
result
qcmd
panel
denv
zikv
viru
chikv
obtain
monitor
perform
panflaviviruspanalphaviruspandengu
assay
use
intern
standard
refer
materi
seen
tabl
result
obtain
use
panspeci
assay
individu
type
primer
probe
demonstr
concord
expect
result
sampl
decod
addit
educ
sampl
detect
particip
laboratori
posit
use
panflaviviruspanalphaviruspandengu
assay
result
indic
assay
perform
well
better
molecular
assay
use
worldwid
pacif
island
suffer
high
burden
mosquitoborn
diseas
report
dengu
serotyp
chikv
zikv
virus
circul
region
peopl
infect
number
may
highli
underreport
time
outbreak
diseas
report
number
includ
denv
serotyp
chikv
zikv
outbreak
outbreak
result
heavi
toll
island
health
system
thu
rapid
test
method
requir
region
enhanc
surveil
assist
critic
respons
measur
limit
spread
diseas
vanuatu
pacif
island
nation
locat
south
pacif
ocean
island
spars
popul
home
popul
around
although
number
dengu
outbreak
occur
island
case
fatal
dengu
drop
reduct
primarili
due
increas
public
awar
earli
detect
manag
furthermor
chickungunya
one
zika
case
record
island
kalki
sero
person
commun
main
referr
hospit
region
port
vila
central
hospit
situat
capit
port
vila
northern
district
hospit
luganvil
port
vila
central
largest
referr
hospit
region
molecular
test
perform
although
port
vila
central
hospit
equip
molecular
diagnost
facil
time
studi
access
molecular
method
detect
flavivirusalphaviru
test
carri
includ
antigen
test
igg
igm
serolog
test
order
confirm
presenc
denv
sampl
sent
new
zealand
order
type
strain
respons
molecular
diagnost
techniqu
could
result
delay
week
confirm
presenc
serotyp
dengu
respons
infect
method
real
time
nest
wide
use
detect
denv
gene
acutephas
serum
sampl
detect
coincid
viremia
febril
phase
ill
onset
addit
advantag
dengu
serotyp
inform
quickli
determin
assist
patient
manag
especi
go
develop
sever
dengu
ill
order
assess
util
panflaviviruspanalphaviruspandengu
assay
outbreak
situat
small
footprint
x
x
cartridg
base
autom
nucleic
acid
extract
platform
gsmini
genet
signatur
australia
use
gsmini
purif
system
process
sampl
singl
run
hour
purif
platform
simpl
use
staff
prior
molecular
experi
compet
process
undergo
minim
train
pcr
perform
mic
real
time
pcr
platform
bio
molecular
system
sydney
australia
footprint
x
x
mic
well
instrument
take
around
hour
complet
run
use
panflaviviruspanalphaviruspandengu
assay
thu
individu
patient
sampl
gsmini
process
singl
run
use
assay
total
turnaround
time
sampl
result
order
hour
minut
thu
patient
inform
result
within
half
day
addit
test
algorithm
inspir
high
degre
confid
three
marker
requir
posit
result
panflaviviru
posit
pandengu
viru
posit
case
particular
outbreak
posit
furthermor
subsequ
confirm
requir
thu
remov
lengthi
process
send
sampl
new
zealand
type
march
sampl
patient
suspect
dengu
infect
screen
use
panflaviviruspanalphaviruspandengu
assay
sampl
cohort
includ
archiv
sampl
fresh
serum
sampl
patient
attend
port
vila
central
hospit
suspect
denv
infect
prior
test
preliminari
studi
undertaken
determin
sampl
mouth
swab
urin
could
use
detect
presenc
denv
instead
invas
blood
test
small
number
patient
present
denvlik
symptom
n
match
mouth
swab
urin
serum
plasma
sampl
obtain
process
although
denv
rna
could
detect
urin
mouth
swab
level
significantli
reduc
compar
match
serumplasma
sampl
due
increas
sensit
obtain
use
serumplasma
sampl
sampl
type
use
subsequ
patient
test
total
patient
sampl
suspect
denv
infect
process
use
system
tabl
gave
tripl
panflaviviru
pandengu
viru
posit
result
sampl
posit
pandengu
assay
howev
sampl
gave
weak
pcr
signal
ct
valu
greater
thu
denv
rna
may
present
llod
assay
unabl
reliabl
detect
serum
sampl
due
time
constraint
possibl
return
sampl
confirm
look
patient
demograph
detail
data
avail
found
femal
case
male
case
denv
infect
patient
cohort
anker
arima
previous
found
excess
male
among
report
denv
case
year
age
howev
support
limit
studi
perhap
due
small
sampl
set
fig
show
weekli
preval
denv
infect
decemb
march
highest
number
dengu
case
report
januari
declin
februari
interestingli
number
case
dengu
infect
increas
month
march
march
coincid
start
routin
test
patient
attend
port
vila
central
hospit
denv
like
symptom
use
panflaviviruspanalphaviruspandengu
molecular
assay
increas
dengu
case
seen
march
may
attribut
increas
sensit
use
molecular
method
compar
convent
eia
fig
show
age
relat
denv
infect
seen
data
number
posit
dengu
case
mirror
age
demograph
island
vanuatu
fig
show
number
denv
dengu
case
island
resid
incid
per
resid
includ
efat
largest
popul
vanuatu
resid
would
expect
also
highest
number
resid
confirm
denv
infect
case
period
test
remaind
island
popul
low
less
gener
number
posit
denv
case
correl
island
popul
island
incid
denv
infect
significantli
differ
averag
nation
incid
per
peopl
howev
island
aniwa
p
amba
p
tongoa
p
ema
p
higher
number
posit
case
would
expect
number
resid
alon
interestingli
island
santo
popul
show
statist
signific
decreas
number
dengu
case
record
per
p
compar
nation
averag
howev
strike
exampl
island
ema
tongoa
amba
amba
popul
confirm
dengu
case
tongoa
ema
resid
total
case
respect
aniwa
case
dengu
home
inhabit
thu
exclud
reservoir
increas
dengu
infect
due
small
popul
case
infect
although
studi
rel
small
total
confirm
case
whole
vanuatu
region
perhap
island
ema
tongoa
amba
higher
number
mosquito
harbour
denv
thu
lead
increas
number
posit
case
observ
resid
island
fig
summari
panflaviviru
panalphaviru
pandengu
assay
high
sensit
specif
use
whole
viral
nucleic
acid
intact
viral
particl
cross
reactiv
observ
wide
rang
nontarget
organ
assay
perform
well
better
assay
use
laboratori
worldwid
test
confirm
refer
materi
intern
standard
qcmd
panflaviviru
panalphaviru
pandengu
viru
pcr
work
well
outbreak
situat
tripl
posit
signal
give
extra
confid
result
panflaviviru
concord
data
avail
interestingli
tripl
posit
rtpcr
sampl
antigen
neg
possibl
due
improv
sensit
assay
result
obtain
hour
enabl
patient
receiv
result
day
autom
extract
platform
pcr
instrument
small
footprint
assay
easi
use
even
staff
formal
molecular
train
make
ideal
use
situat
limit
resourc
final
assay
describ
would
ideal
suit
gener
screen
tool
vector
surveil
studi
flaviviru
alphaviru
quickli
sensit
detect
regardless
geograph
region
virus
endem
region
